We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Despite Deficient Trial Data, Novartis Wins Panel Support for Tobi Alternative
Despite Deficient Trial Data, Novartis Wins Panel Support for Tobi Alternative
September 12, 2012
The FDA’s Anti-Infective Drugs Advisory Committee has recommended the FDA approve Novartis’ inhaler-based version of cystic fibrosis (CF) drug Tobi, despite deficient supporting clinical study data.